A Randomized, Double-blind and Single-dose Study to Compare the Pharmacokinetic and Safety of QL1203 and Vectibix in Healthy Male Subjects
Latest Information Update: 07 Jan 2022
At a glance
- Drugs QL 1203 (Primary) ; Panitumumab
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 23 Jan 2020 New trial record